• Mubritinib (TAK 165): Protocols for Mitochondrial & HER2 Stu

  2026-05-20

  Mubritinib (TAK 165) redefines cancer research by targeting both mitochondrial complex I and HER2 signaling pathways, enabling precise modeling of chemotherapy resistance and cell metabolism. This guide delivers actionable protocols, advanced troubleshooting, and data-backed insights for translational scientists.

• 4μ8C and the Future of Unfolded Protein Response Inhibition

  2026-05-20

  This thought-leadership article explores the mechanistic and translational landscape of 4μ8C, a highly selective IRE1α RNase inhibitor. Blending recent advances in ER stress signaling with actionable strategic guidance, it positions 4μ8C as an indispensable tool for cancer researchers and translational scientists aiming to dissect the unfolded protein response (UPR) with precision. The article contextualizes 4μ8C’s unique capabilities, critically appraises its limitations, and outlines the broader implications for future disease modeling and therapeutic innovation.

• L-NMMA Acetate: Precision Inhibition of NOS in Osteogenic Mo

  2026-05-19

  Explore how L-NMMA acetate enables precise modulation of the nitric oxide pathway in osteogenic differentiation research. This article offers a unique, in-depth analysis on NOS inhibition in dental follicle cell models, advancing beyond general inflammation and cardiovascular focuses.

• D-N-Acetylgalactosamine: Technical Parameters for Brain Glyc

  2026-05-19

  D-N-Acetylgalactosamine is a high-purity, water-soluble standard essential for investigating glycoprotein structures and glycosylation pathways in brain tissue. It is unsuitable for workflows requiring ethanol solubility or storage of working solutions for extended periods. Proper handling and workflow design are critical to ensure reproducible results.

• EdU Imaging Kits (488): Precision Cell Cycle Analysis in Can

  2026-05-18

  Explore how EdU Imaging Kits (488) empower advanced, precise cell proliferation assays using 5-ethynyl-2'-deoxyuridine. This article uniquely integrates mechanistic insights and translational relevance for oncology and immunology research.

• FOXM1-Driven ceRNA Networks in Female Lung Adenocarcinoma

  2026-05-18

  This study identifies and validates a novel competitive endogenous RNA (ceRNA) network involving FOXM1 and estrogen receptor 1 in female lung adenocarcinoma (LUAD). The findings clarify the prognostic significance of FOXM1 expression and its role in tumor progression, with implications for targeted therapies and immunotherapy responsiveness.

• Estradiol–Autophagy Axis: Multi-Organ Protection in Perimeno

  2026-05-17

  This study reveals that reduced 17 beta-estradiol levels during perimenopause are strongly linked to increased risk of cardiovascular, renal, and metabolic diseases. Using integrated human cohort data, network pharmacology, and mouse models, the research demonstrates that estrogen’s protective effects in heart, aorta, and kidneys rely on receptor-mediated autophagy, offering mechanistic insight for precision hormone therapy.

• Liproxstatin-1: Precision Ferroptosis Inhibitor for Cell Dea

  2026-05-16

  Liproxstatin-1 empowers researchers to dissect and control ferroptotic cell death with nanomolar precision, making it indispensable for GPX4-deficient, renal, and organ injury models. This article details robust workflows, troubleshooting strategies, and latest mechanistic insights for optimal use of Liproxstatin-1 in applied ferroptosis research.

• Controlling Lipid Nanoparticle Size for Optimized mRNA Deliv

  2026-05-15

  This study investigates how manufacturing parameters, specifically aqueous-to-lipid phase ratios, precisely control the size of lipid nanoparticles (LNPs) and subsequently impact mRNA expression in vitro and in vivo. The findings provide actionable insights for optimizing LNP-mediated mRNA delivery, crucial for both therapeutic development and molecular biology research.

• Ceftolozane Sulfate: Mechanism, Assay Innovation, and PK/PD

  2026-05-15

  Explore the advanced mechanism and in vitro assay strategies for Ceftolozane sulfate. This in-depth analysis reveals how its unique PBP3 targeting and β-lactamase stability inform robust antibacterial testing and PK/PD optimization, setting new standards beyond current literature.

• Cefazedone (Refosporen): Mechanism, Evidence & Protocols

  2026-05-14

  Cefazedone (Refosporen) is a first-generation cephalosporin antibiotic with robust, β-lactamase-resistant activity against both Gram-positive and Gram-negative bacteria. Its primary mechanism is inhibition of bacterial cell wall synthesis, and its pharmacokinetics have been rigorously validated in both preclinical and clinical settings.

• Spatially Concentrated Base Editors Correct PLP1 Mutations i

  2026-05-14

  This study introduces a spatially concentrated adenine base editor (cABE) system that enables efficient and precise correction of pathogenic PLP1 mutations in oligodendrocytes, a key challenge in treating Pelizaeus–Merzbacher disease (PMD). The approach leverages subcellular targeting to improve editing efficiency and fidelity, offering a new technical paradigm for gene therapy in myelin disorders.

• Palbociclib (PD0332991): Applied Workflows in Cancer Models

  2026-05-13

  Palbociclib (PD0332991) Isethionate empowers translational research by enabling precise control of G0/G1 cell cycle arrest and apoptosis induction in physiologically relevant tumor models. This article delivers hands-on workflow optimizations and troubleshooting tips for integrating Palbociclib into assembloid and organoid assays, accelerating both mechanistic insights and next-generation drug screening.

• Cell lysis buffer for WB and IP: Mechanism, Use, and Evidenc

  2026-05-13

  Cell lysis buffer for WB and IP offers robust, non-denaturing protein extraction with broad applicability to animal, plant, and microbial samples. Its protease and phosphatase inhibitor cocktail preserves protein integrity, enabling reliable results in Western blot and immunoprecipitation workflows. This article details the buffer’s formulation, mechanistic rationale, validated benchmarks, and practical boundaries.

• Methoxy-X04 for Reliable Amyloid Beta Imaging: Laboratory Sc

  2026-05-12

  This article addresses common laboratory challenges in amyloid beta detection and imaging, illustrating how Methoxy-X04 (SKU B5769) delivers reproducible, high-contrast results in Alzheimer’s disease research. Scenario-driven Q&A blocks provide evidence-backed guidance on protocol optimization, data interpretation, and supplier selection, supporting informed choices for advanced neurodegenerative disease workflows.

443 records 17/30 page Previous Next First page 上5页 1617181920 下5页 Last page